Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and keeping the price target at $4.00.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Actinium Pharmaceuticals’ innovative approach and promising developments. The enrollment of the first patient in a unique clinical trial at the University of Texas Southwestern Medical Center marks a significant milestone for the company. This trial evaluates Iomab-ACT, a targeted radiotherapy conditioning agent, in combination with commercial CAR-T therapy. Iomab-ACT aims to replace traditional chemotherapeutic conditioning agents and mitigate serious CAR-T related toxicities, potentially improving patient outcomes and accessibility.
Additionally, Actinium’s recent presentation at AACR ’25 showcased encouraging preclinical data on their pipeline assets, Actimab-A and ATNM-400. The data revealed promising results in tumor growth inhibition and survival in prostate cancer models, as well as enhanced anti-leukemic activity in AML models. These advancements, coupled with the significant market opportunity for novel conditioning agents, underpin Pantginis’s positive outlook on Actinium Pharmaceuticals, leading to the Buy rating.
In another report released on April 30, JonesTrading also reiterated a Buy rating on the stock with a $9.00 price target.